Immuneering CORP Form 4 insider transactions

Peter Feinberg, a director of Immuneering Corp, reported the acquisition of stock options on June 12, 2024.

Director Ann E. Berman reported the acquisition of stock options in Immuneering Corp, vesting monthly over one year starting July 12, 2024.

Director Diana Hausman acquired 33,350 stock options in Immuneering Corp on June 12, 2024.

Michael Bookman, Chief Legal Officer and Secretary of Immuneering Corp, had his stock options repriced to $3.01 per share on May 21, 2024, as approved by the Issuer's Board of Directors.

Mallory Morales, Chief Accounting Officer of Immuneering Corp, had stock options repriced to $3.01 per share, according to a recent SEC filing.

Harold Eugene Brakewood, Chief Business Officer of Immuneering Corp, had stock options repriced to $3.01 per share, according to a Form 4 filing.

Leah R. Neufeld, Chief People Officer of Immuneering Corp, had her stock options repriced to $3.01 per share on May 21, 2024, as approved by the Issuer's Board of Directors.

Cormorant Asset Management, along with related entities, reports a decrease in beneficial ownership of Immuneering Corp Class A Common Stock following a series of transactions on April 1, 2024.

Director Thomas J. Schall of Immuneering Corp [IMRX] purchased 2,900 shares of Class A Common Stock on March 22, 2024, at an average price of $2.5465 per share.

Director Peter Feinberg increased his holdings in Immuneering Corp (IMRX) by purchasing 25,000 shares of Class A Common Stock at an average price of $2.5485 on March 22, 2024.

Harold Eugene Brakewood, Chief Business Officer of Immuneering Corp, purchased 3,900 shares of Class A Common Stock at $2.568 per share on March 22, 2024.

Mallory Morales, Chief Accounting Officer of Immuneering Corp, reports acquiring shares of Class A Common Stock through the company's Employee Stock Purchase Plan and open market purchases.

Leah R. Neufeld, Chief People Officer of Immuneering Corp, reports acquiring shares of Class A Common Stock through the company's Employee Stock Purchase Plan and open market purchases.

Brett Matthew Hall, Chief Scientific Officer of Immuneering Corp, reports acquiring shares of Class A Common Stock through the company's Employee Stock Purchase Plan and open market purchases.

Michael Bookman, Chief Legal Officer and Secretary of Immuneering Corp, reports acquiring 1,448 shares of Class A Common Stock through the company's Employee Stock Purchase Plan (ESPP) on March 15, 2024.

Director Ann E. Berman reports purchasing 57,965 shares of Immuneering Corp (IMRX) at an average price of $2.1295 on March 18, 2024, increasing her holdings to 67,465 shares.

Peter Feinberg, a director at Immuneering Corp, recently increased his holdings of Class A Common Stock through a series of purchases.

Immuneering Corp's CEO, Benjamin J. Zeskind, purchased 20,000 shares of Class A Common Stock at an average price of $2.7663 on March 19, 2024.

Cormorant Asset Management, along with related entities, sold shares of Immuneering Corp (IMRX) in a series of open market transactions on March 14 and 15, 2024.

Director Thomas J. Schall reports acquisition of 35,000 stock options in Immuneering Corp.